ArticleCommunications medicine2026
Assessment of pneumonitis in patients with lung cancer undergoing radioimmunotherapy and immune checkpoint inhibitor rechallenge.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Optimal treatment strategies for unresectable stage IIIFrontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe combination of immune checkpoint inhibitors (ICIs) with radiotherapy (RT) has improved survival in patients with advanced lung cancer, yet treatment-related pneumonitis (TRP) is highly toxic. Current limitations include the absence of robust risk stratification models for TRP and unclear safety criteria for ICI rechallenge, hindering the management of recurrent TRP (rTRP).
methodsIn this multicenter retrospective study, we analyzed 262 lung cancer patients receiving radioimmunotherapy. The data included baseline demographics, immunotherapy regimens, and radiotherapy parameters. TRP was graded per CTCAE v5.0. Univariate and multivariate logistic regression identified predictors of TRP and rTRP severity.
resultsThe incidence of TRP is 57.6% (151/262), with grade 1, 2, and ≥ 3 TRP occurring in 24.4%, 25.6%, and 7.6% of patients, respectively. The median time to TRP onset is 113 days (IQR, 73-155). Multivariate analysis reveals PD-1 inhibitors and ICI cycle number as predictors of G ≥ 1 TRP, whereas Dmean predicts all grades. Dose‒response modeling reveals Dmean thresholds for 50% TRP risk: 8.7 Gy (G ≥ 1), 15.3 Gy (G ≥ 2), and 23.4 Gy (G ≥ 3). Among the 53 patients receiving ICI rechallenge, 25.4% (13/53) developed rTRP. Rechallenge within 4 weeks significantly increases rTRP risk (OR, 0.061; 95% CI, 0.010-0.368; P = 0.002).
conclusionsDmean serves as a continuous risk modifier for TRP severity, with Dmean > 15.3 Gy associated with grade ≥ 2 toxicity. An interval of ≥ 4 weeks after TRP is proposed as a safety window for ICI rechallenge, addressing critical gaps in radioimmunotherapy toxicity management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.